Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study | JCO Precision Oncology
PURPOSETargeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic alterations. Two cohorts of patients …Palbociclib met @ASCO #TAPUR criteria to declare antitumor activity in patients with CDKN2A-altered HNC.